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Abstract
Dietary supplements are increasingly marketed to and consumed by the American public for a 
variety of purported health benefits. On 9 September 2013, the Hawaii Department of Health 
(HDOH) was notified of a cluster of acute hepatitis and fulminant hepatic failure among 
individuals with exposure to the dietary supplement OxyELITE Pro™ (OEP). HDOH conducted 
an outbreak investigation in collaboration with federal partners. Physicians were asked to report 
cases, defined as individuals with acute onset hepatitis of unknown etiology on or after 1 April 
2013, a history of weight-loss/muscle-building dietary supplement use during the 60 days before 
illness onset, and residence in Hawaii during the period of exposure. Reported cases’ medical 
records were reviewed, questionnaires were administered, and a product investigation, including 
chemical analyses and trace back, was conducted. Of 76 reports, 44 (58%) met case definition; of 
these, 36 (82%) reported OEP exposure during the two months before illness. No other common 
supplements or exposures were observed. Within the OEP-exposed subset, two patients required 
liver transplantation, and a third patient died. Excessive product dosing was not reported. No 
unique lot numbers were identified; there were multiple mainland distribution points, and lot 
numbers common to cases in Hawaii were also identified in continental states. Product analysis 
found consumed products were consistent with labeled ingredients; the mechanism of 
hepatotoxicity was not identified. We report one of the largest statewide outbreaks of dietary 
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supplement-associated hepatotoxicity. The implicated product was OEP. The increasing popularity 
of dietary supplements raises the potential for additional clusters of dietary supplement-related 
adverse events.
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Introduction
More than half of adults in the United States use dietary supplements, most commonly to 
‘improve’ or ‘maintain’ overall health.[1] Weight-loss supplements are especially 
popular.[2,3] Although dietary supplements often appear in a capsule or tablet similar to 
prescription medicine, they are regulated as food and not subjected to the same premarket 
requirements for safety or efficacy; thus, post-market surveillance and epidemiology are the 
only means of identifying problems in the marketplace and protect consumers.
Over 1100 agents, including drugs and herbs, are recognized to cause liver injury.[4] 
However, attributing causality is often challenging given the limited clinical laboratory tests 
to identify specific hepatotoxins.[5] Hepatotoxicity has been previously reported as a serious 
adverse reaction to dietary supplement consumption; a study of 20 cases of fulminant 
hepatic failure seen by a liver transplantation service found half of the cases were active or 
recent users of dietary supplements with known potentially hepatotoxic supplements or 
herbs, with 7 cases having no other etiology identified.[6] A review of the United Network 
for Organ Sharing liver transplant database from 1990 to 2002 demonstrated an ‘herbal’ 
etiology in 5% of 270 people who received transplantation for drug-induced 
hepatotoxicity.[7]
On 9 September 2013, clinicians at Hawaii’s single liver transplant centre notified the 
Hawaii Department of Health (HDOH) of seven previously healthy adults who had 
presented with acute and/or fulminant hepatitis of unknown etiology since May 2013. A case 
series describing the clinical course of their cases has been published previously.[8] The 
clinicians reported all cases had used the dietary supplement OxyELITE Pro™ (OEP), 
containing per product labelling ‘proprietary blends of plant-derived extracts’ (Table 1), for 
weight-loss or muscle-building before illness onset. Given the potential association with a 
commercial product and the patients’ serious conditions, HDOH, with the Centers for 
Disease Control and Prevention (CDC) and Food and Drug Administration (FDA), initiated 
a public health investigation.
We report here the findings and conclusions of that epidemiologic investigation and the 
public health actions taken in response. This report contributes to the published literature on 
dietary supplement-associated hepatitis, and provides the findings from the epidemiological 
investigation and more in-depth examination of the events in Hawaii, initially uncovered by 
the cases depicted in the case series by Roytman et al.[8] Additionally, this report serves as a 
final update and offers resolution to the brief description of preliminary findings that was 
published early in our investigation.[9]
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A case was defined as an individual with acute onset hepatitis of unknown etiology on or 
after 1 April 2013, who had a history of weight-loss/muscle-building dietary supplement use 
during the 60 days before illness onset, and had lived in Hawaii during the period of 
exposure. The date – 1 April – was selected to detect cases that may have had onset before 
the earliest onset of the first seven reported cases. Acute onset hepatitis of unknown etiology 
was defined as both an alanine aminotransferase (ALT) level four times the normal upper 
limit and a total bilirubin (TBili) level twice the normal upper limit without other explicative 
diagnosis. A probable case required a medical evaluation that excluded alternative 
explicative etiologies, specifically: hepatic imaging not consistent with an alternative 
etiology; no evidence of acute hepatitis A or acute or chronic hepatitis B and C infection; no 
pre-existing chronic liver disease; no recent hypotensive shock or septic episodes; and no 
history of alcoholism. Further work-up for less common causes of acute fulminant hepatitis 
(e.g. autoimmune markers, hepatitis E serologies) was performed at the discretion of the 
diagnosing physician. A patient meeting probable criteria but without complete 
documentation of a negative work-up for infectious or other explicative etiologies for 
hepatitis including at least a negative viral hepatitis testing and hepatic imaging not 
consistent with alternative, explicative etiologies was considered a suspect case.
Epidemiologic investigation
Case finding—On 25 September 2013, HDOH emailed and faxed a statewide medical 
advisory requesting clinicians report anyone presenting in the last six months with hepatitis, 
jaundice, or hyperbilirubinemia concomitant with weight-loss/muscle-building dietary 
supplement use. A six-month period was chosen to promote ease of recall by the providers 
while ensuring adequate detection of earlier-onset cases. Additionally, a 26 September 2013 
press release[10] alerted the public regarding the investigation, potential symptoms, and 
advised using dietary supplements only under a physician’s supervision. HDOH requested 
all medical records for all those meeting at least suspect case criteria.[11] Case collection for 
the purposes of the initial investigation was closed as of 1 November 2013 although HDOH 
continued to collect reports of acute hepatitis in individuals with OEP exposure after this 
date.
Data collection—A standardized questionnaire administered by phone or in person 
elicited patient demographics; comorbidities; clinical symptoms and course; and exposures 
of interest including alcohol use, prescription and over-the-counter medications including 
Tylenol® (acetaminophen), home remedies, and any dietary supplements. As initial cases 
had reported OEP (USPLabs, LLC, Dallas, TX, USA) exposure, we queried this specifically 
as well as any other supplements consumed during the two months before illness. Dosage, 
exposure dates, purchase dates, purchase location, and shopper loyalty programme 
information were obtained when possible. When precise dates could not be recalled, we 
imputed a date (e.g. 1 May for ‘beginning of May’, 15 May for ‘middle’, and 28 May for 
‘end’). To ensure this did not affect our results, data were analyzed with and without the 
estimated dates.
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We used a standardized medical chart abstraction form to collect clinical course and 
laboratory, radiological, and pathology findings. A Council for International Organizations 
of Medical Sciences (CIOMS) score for hepatocellular injury as described by Teschke et 
al.[12,13] was assigned for cases reporting OEP consumption to estimate potential causality. 
The CIOMS scale is a suspected herb-induced hepatotoxicity causality assessment method 
that incorporates timing of supplement exposure to illness onset, evaluation for alternative 
diagnoses, and exposures to other potential hepatotoxins; it estimates causality as ‘highly 
probable’, ‘probable’, ‘possible’, ‘unlikely’, and ‘excluded’.[12–15]
Product investigation
HDOH environmental inspectors queried Hawaii dietary supplement retailers on OEP sale 
and distribution information. The number of units of all weight-loss dietary supplements 
sold in Hawaii from January–September 2013 was requested from retail chains to estimate 
OEP market share in Hawaii.[16]
HDOH collaborated with the FDA to collect any remaining product from cases. Lot numbers 
and detailed product and container pictures were obtained. Product was forwarded to the 
FDA’s Forensic Chemistry Center (FCC) in Cincinnati, OH, for testing. For all submitted 
samples, liquid chromatography-mass spectrometric (LC-MS) detection was used as a 
general screen to identify a variety of drugs, poisons, and other active constituents. Liquid 
chromatography with ultraviolet detection was used to confirm and quantify the amounts of 
the labeled ingredients aegeline and higenamine (norcoclaurine HCL) reported by the 
manufacturer.
On a representative sub-sample of products from Hawaii cases, a more comprehensive set of 
analyses were performed, including liquid chromatography-high resolution mass 
spectrometry (LC-HR/MS) and gas chromatography–mass spectrometric (GC-MS) detection 
targeted screens for compounds previously identified in investigations as potential 
hepatotoxins,[13,17] such as pyrrolizidine alkaloids, N-nitrosofenfluramine, catechins, usnic 
acid, phenethylamines, and aristolochic acid. Inductively coupled plasma mass spectrometry 
(ICP-MS) was used to screen for the presence of toxic elements or potentially harmful levels 
of other elements.
Data analysis
All data were entered into a Microsoft Excel database (Microsoft, Redmond, CA, USA), and 
ArcGIS (ESRI, Redlands, CA, USA) was used to map cases statewide. Data were analyzed 
using SAS 9.3 (SAS Institute Inc., Cary, NC, USA), and descriptive case statistics were 
generated. Comparisons were performed between cases who took OEP, either alone or with 
other supplements, and those who only took other supplements. Differences between those 
hospitalized versus not hospitalized and those who stopped taking OEP at or before onset of 
illness versus those who continued taking it were also compared. Differences in proportions 
were compared using Chi-squared test or Fisher’s exact test, and comparisons between pairs 
of group medians were examined using Wilcoxon rank-sum test. A Bonferroni correction 
and bootstrap methodologies were applied to account for multiple comparisons.
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Summary of all cases—As of 1 November 2013, we received 76 reports of acute 
hepatitis of unknown etiology (Figure 1). The epidemiological curve of the 44 reports 
meeting case criteria by illness onset is shown in Figure 2, and demographics for these 44 
cases are presented in Table 2. Patients were distributed across all Hawaii counties with no 
geographic clustering.
Thirty-six (82%) cases reported taking OEP (Table 3). Only one other supplement for weight 
loss or muscle gain was common to multiple cases. Three cases reported using that other 
supplement; two of those also reported OEP exposure. In 16 (57%) of 28 cases with records 
dated before the first medical advisory, physicians documented suspicion of supplement-
related hepatotoxicity, with OEP specifically noted in 8 (29%). All cases reported taking the 
manufacturer-recommended daily dose, 1–3 (median 2) capsules or scoops. After Bonferroni 
correction, no significant differences were found in demographics (listed in Table 2), 
symptoms, other exposures, laboratory values and symptom duration (both listed in Table 4), 
and length of hospital stay among OEP-exposed (alone or with other supplements) cases and 
other supplement-exposed cases. Similarly, there were no differences in demographics, 
symptoms, and laboratory values between those hospitalized versus not hospitalized and 
those who stopped taking OEP at or before illness onset versus those who continued.
All 36 OEP-exposed cases reported having dark urine, and almost all (92%) reported 
yellowing of the eyes or skin, loss of appetite, and fatigue (Table 4). Radiological imaging 
did not reveal biliary obstruction or alternative diagnoses. Of 12 cases who underwent liver 
biopsy, findings for 8 demonstrated inflammation and necrosis consistent with drug or toxic 
injury. Causality assessment using the CIOMS scale showed that 94% of cases were in the 
‘possible’ and ‘probable’ range (Table 3).
Additional outbreak cases—After case collection for the initial investigation ended on 1 
November 2013, we continued to collect reports of acute hepatitis in individuals with OEP 
exposure. An additional 8 OEP-exposed cases were identified; only one occurred outside the 
onset range of the original 36 cases (9 November 2013). Demographic, clinical, and 
exposure data for these cases were compared to and found not significantly different from 
the initial 36 cases.
Illustrative cases
Case 1—A 28-year-old female without co-morbidities presented on 6 June 2013 to her 
physician with anorexia and nausea, one week of fatigue and yellowing skin, and two weeks 
of ‘yellowing in both eyes’. Laboratory work-up yielded ALT 1420 IU/L, aspartate 
aminotransferase (AST) 1390 IU/L, alkaline phosphatase (ALP) 166 IU/L, and TBili 6.9 
mg/dL. Viral hepatitis serologies were negative. She later reported that she had been taking 
OEP before onset and continued after this visit for another month and then stopped, with 
improvement in symptoms. She restarted OEP in September and was seen in a local 
emergency department on 17 September for lightheadedness, subjective fevers, nausea, 
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emesis, and abdominal pain. Her ALT was 150, AST 200, ALP 100, and TBili 1.1. She 
stopped OEP again after hearing media reports in late September and presented to her 
physician on 9 October with similar symptoms as previously. She was subsequently admitted 
10 October with ALT 1494, AST 1446, ALP 197, and TBili 3.3. An ultrasound 
demonstrated heterogeneous liver parenchyma consistent with hepatitis. She was treated 
supportively and was clinically improving when discharged on 17 October 2013. Her 
CIOMS score was determined to be 8, suggesting a ‘probable’ supplement or drug-related 
liver injury.[13]
Case 2—A 42-year-old female without co-morbidities presented on 18 September 2013 
with four days of intractable nausea, emesis, and diarrhoea to her physician, who 
administered intravenous fluids. On 22 September, she presented to a local emergency 
department with altered mental status and history of taking OEP with ~2 pounds per day 
weight loss, which continued despite stopping OEP on 7 September. Laboratory values on 
22 September demonstrated ALT 835, AST 537, ALP 139, and TBili 23.9. She was 
transferred to the state’s transplant centre on 23 September with evidence of coagulopathy 
(prothrombin time 35.7, INR 4) and developed hepatic encephalopathy on 24 September. 
Her work-up was negative for alternative etiologies. Her encephalopathy worsened, and she 
was intubated and transferred to the intensive care unit on 26 September. An emergent liver 
transplantation work-up revealed ductal carcinoma in situ of the breast, precluding liver 
transplantation. Despite aggressive care, she developed cerebral oedema and died on 4 
October 2013. This case’s CIOMS score was ultimately determined to be 7, also suggesting 
a ‘probable’ supplement or drug-related injury.[13]
Product investigation
Review of product distribution from January to September 2013 in Hawaii demonstrated two 
types of OEP available for purchase: a 1,3-dimethylamylamine (DMAA)-containing OEP 
(the ‘original’ OEP formula) and multiple DMAA-free OEP formulations (comprising 
several different formulas). USPLabs began producing DMAA-free OEP formulations in 
lieu of DMAA-containing OEP starting in late 2012 after the FDA issued a warning letter[18] 
on 24 April 2012 advising USPLabs that it had failed the legal requirement to inform the 
FDA of the basis for concluding that dietary supplements containing a new dietary 
ingredient (i.e., DMAA) would reasonably be expected to be safe. While the DMAA-free 
formulas became available in late 2012, the original formula was still available and being 
purchased through July 2013. Case onset dates appeared to correlate with the increasing 
popularity of DMAA-free OEP formulations. From January to September 2013, in Hawaii, 
an average of 6912 units per month of weight-loss supplements, 43% of which were OEP, 
was sold.
Table 3 demonstrates the OEP product types purchased by cases; the overwhelming majority 
(83%) used at least one DMAA-free formulation. Of the cases that used the DMAA-free 
formulation, the majority reported using the Super Thermo capsules; only four (11%) 
reported using Super Thermo Powder, half of whom also reported using Super Thermo 
capsules. Product was purchased from multiple retailers; six cases purchased product online. 
Product was collected from 13 cases (10 on Oahu, 3 on Hawaii Island). No common lot 
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number was identified. Investigation-associated lot numbers were identified among products 
in other states, and retailers reported ordering product as needed, with product shipped 
directly from multiple continental distribution points.
A total of 18 product samples patients from Hawaii were submitted to the FDA’s FCC. All 
underwent initial screening with five undergoing more extensive testing; LC-HR/MS, GC-
MS, and ICP-MS screening detected none of the targeted hepatotoxins, drugs, poisons, or 
toxic elements. Substances identified in the samples were consistent with ingredients and 
levels indicated in the product formulations provided by the manufacturer.
Outbreak response in Hawaii
HDOH issued an embargo on all OEP products sold in the state on 8 October 2013, and 
alerted the public via a press release;[19] concurrently, a medical advisory requested 
clinicians advise patients to discontinue OEP use immediately and seek medical care for 
compatible symptoms. HDOH promoted public education on supplement safety with an 
online ‘frequently asked questions’ resource.[20] A 18 November 2013 press release[21] 
alerted the public that HDOH was notifying retailers to voluntarily destroy the embargoed 
OEP or surrender it to HDOH for collection and destruction. This action followed a 
voluntary OEP recall by USPLabs.[22]
Eighty-two percent of our cases reported OxyELITE Pro™ consumption; no other common 
supplement or exposure was identified. Our cases’ clinical presentations could arguably be 
consistent with other hepatitis etiologies; however, our case definition excluded cases with 
known etiologies. One case re-challenged herself with OEP and developed hepatitis that 
resolved after discontinuation. Excessive daily dosing of OEP or other medications like 
Tylenol® (acetaminophen) and NSAIDs was not reported. Finally, even before the outbreak 
was identified, case clinicians documented dietary supplement, specifically OEP, 
hepatotoxicity.
Interpretation
As in previously reported cases of hepatotoxicity associated with dietary supplements, a 
causal link between exposure and hepatotoxicity was difficult to assess.[12] However, we 
estimated the majority of cases to be ‘possible’ or ‘probable’ using the CIOMS-based scale, 
a preferred causality assessment method validated previously and used in multiple 
reports.[12] Despite limitations, CIOMS-based assessment has reasonable sensitivity (86%), 
specificity (89%), and positive predictive value (93%).[13] In herb-associated hepatotoxicity 
cases judged ‘possible’ or higher, liver histology findings were similar;[13] others have 
reported the majority of herb/dietary-associated hepatotoxicity cases have a ‘possible’ 
CIOMS rating.[15]
Other reports of dietary supplements associated with hepatotoxicity have been reported in 
recent years.[23–27] Case presentations and findings, including variability in duration of 
product use before illness onset and course severity, among these reports appear similar to 
each other and to our cases. As elsewhere,[27] almost a third of our cases demonstrated 
positive autoimmune markers; however, the significance is unclear. The clinical course and 
outcome of our cases appeared to be independent of age, dose, or exposure duration as 
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observed with other hepatotoxic supplements.[23,24] Others have noted that outcome appears 
related only to the degree of liver dysfunction and not to any particular demographic factor 
or aspect of supplement consumption.[4]
The FDA has warned the manufacturer that the DMAA-free formulations contain aegeline, a 
plant-derived compound used in Ayurvedic medicine, that is considered ‘a new dietary 
ingredient’ (i.e., not marketed in the United States before 15 October 1994) and therefore 
requires federal notification and evidence that products containing it are ‘reasonably 
expected to be safe, under the conditions of use described in the labeling’.[28] Whether 
aegeline, or another ingredient(s), is the etiologic hepatotoxic agent is not yet known and 
may remain unanswered, as with other supplement investigations. An unrecognized race-
dependent pharmacogenetic factor (e.g. genetic polymorphisms involving drug metabolism) 
is possible; some have reported an excess of Asian/Pacific Islanders among supplement-
associated hepatotoxicity cases,[6,29] while others have reported excess cases among other 
minority groups[7,27] or a general overrepresentation by minorities.[4] However, race-
dependent factors are unlikely to be readily determined here, given the majority of cases 
reported mixed racial/ethnic origin as commonly observed among Hawaii’s population. 
After controlling for differences in data collection methods between our investigation and 
federal census data, the racial background of our cases did not vary greatly from US Census 
data for Hawaii.
The investigation of this single outbreak in Hawaii had important implications for multiple 
sectors of healthcare and public health. Our epidemiologic investigation focused on 
determining the most likely cause of illness in Hawaii’s cases with the ultimate purpose of 
protecting the health of Hawaii’s residents through implementation of specific health or 
control measures; the clinical case series published by Roytman et al. focused on the 
presentation and subsequent clinical course of patients with hepatitis within their clinic who 
reported OEP use.[8] Additionally, after being alerted of the cases in Hawaii, the CDC 
investigated reports meeting similar case criteria in multiple other states. The cases 
identified from these reports and the cases from Hawaii were included in a separate national 
investigation; findings of that investigation will be published in a forthcoming article in 
Drug Testing and Analysis. Furthermore, the impact of national adverse event reporting 
through FDA MedWatch, the only official mechanism for reporting and tracking drug and 
dietary supplement adverse events,[30] and the FDA investigation of and response to this 
outbreak from the federal regulatory perspective were examined; those data are in 
publication.[31] Possible cases in other countries have also been reported.[32,33]
Our investigation is limited by a dearth of studies or surveillance data to provide baseline 
incidence of supplement- or even drug-associated idiosyncratic hepatitis, although it does 
provide a starting point to develop such data. With over 85 000 dietary supplement products 
on the market, background rates of events associated with a given product or ingredients are 
largely unknown.[34] While lack of understanding of the pathogenesis and likely disease risk 
factors as well as a relatively small sample size for comparisons further hindered the ability 
to identify the specific etiology of OEP hepatotoxicity and associated risk factors, our 
findings add further depth to the existing literature on dietary supplement-related 
hepatotoxicity. Although widespread media exposure could have contributed reporting bias 
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and limited identification of cases related to other dietary supplements, our case-finding did 
identify cases of idiopathic hepatitis without OEP exposure; yet, no other commonality 
emerged. Lastly, for unknown reasons, many OEP consumers appear to have remained 
unaffected; asymptomatic presentation with abnormal liver function tests is possible and has 
been reported previously.[15,25] Ultimately, the large number of severe hepatitis cases with 
OEP exposure and no other clear etiology, occurring in a matter of months, suggests a likely 
association that requires further examination.
Drug-induced liver injury has an estimated prevalence of 1/10 000–1/100 000; studies have 
shown approximately 10–16% of those are thought to be caused by herbal or other dietary 
supplements.[4,35] Yet, the true incidence is unknown, partly because of underreporting.[36] 
Systematic identification of these events, however, is problematic. Currently, federal law 
does not require review and approval of herbal products for safety and effectiveness before 
marketing,[2,37] although the 2006 amendment to the federal Food, Drug, and Cosmetic 
Act[38] required industry to report all serious dietary-supplement-related adverse events to 
the FDA. Adverse events associated with pharmaceuticals or dietary supplements are not 
reportable to state or local health departments and would likely be unrecognized except as 
part of a substantial outbreak. Additionally, identifying adverse events related to 
supplements is challenging clinically when many patients tend not to report supplement 
use,[3,39] given that supplements are not marketed or sold as medications. Soliciting 
supplement history would greatly augment clinical care. The situation is further confounded 
by the fact that initial hepatitis symptoms (i.e., loss of appetite, abdominal discomfort) could 
be misinterpreted by patients as weight-loss supplement effectiveness. The case with self-
rechallenge is an example of the product’s popularity and possible denial of association with 
health problems as observed with other weight-loss supplements.[26]
We still do not understand the mechanism of action for many dietary supplements, their 
pharmacologically active components, or their potential interactions with other agents 
including regular medications. Given the popularity of these products, their likelihood to be 
used to self-manage conditions, and the potential for serious adverse events, an improved 
understanding of the safety and efficacy of these products could positively impact public 
health.
Conclusion
HDOH identified a total of 44 individuals with acute onset hepatitis of unknown etiology on 
or after 1 April 2013 with a history of weight-loss/muscle-building dietary supplement use 
during the 60 days before illness onset and residence in Hawaii during the exposure period, 
all with symptom onset dates ranging from April through October, 2013 (Figure 2). Of those 
cases, 36 (82%) reported exposure to the dietary supplement OEP; no other significant 
common exposures were identified. Two of the OEP-exposed cases required liver transplants 
and one OEP-exposed case died. As a result of the findings of the statewide investigation, an 
embargo was issued against all OEP products sold in Hawaii; then, following a national 
recall of the OEP products, HDOH notified retailers to voluntarily destroy their supply or 
surrender it to HDOH for destruction.
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We still do not understand the mechanism of action for many dietary supplements, their 
pharmacologically active components, or their potential interactions with other agents 
including regular medications. Given the popularity of these products, their likelihood to be 
used to self-manage conditions, and the potential for serious adverse events, an improved 
understanding of the safety and efficacy of these products could positively impact public 
health.
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Hepatitis case investigation determination flow-chart, Hawaii, 2013.
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Onset of hepatitis of unknown etiology by supplement taken, Hawaii, April–October 2013 
(N=44).
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Table 1
OxyELITE Pro™ product ingredients
DMAA-Containing Product (Available for purchase through July 2013)
OxyELITE Pro® – Super Thermogenic™*
Serving Size 1 Capsule Amount per serving
  Proprietary Blend 119.5 mg
    Bauhinia Purpurea L.(Leaf and Pod) Extract,
    Bacopa (Leaf)(Bacopa Monnieri) Extract,
    1,3-Dimethylamylamine HCl, Cirsium Oligophyllum
    (Plant) Extract, Yohimbe (Pausinystalia Johimbe) Bark Extract
  Caffeine 100 mg
DMAA-Free Products (Available for purchase late 2012–October 2013)
OxyELITE Pro® – Super Thermo™ (New Formula)*
Serving Size 1 Capsule Amount per serving
  Proprietary Blend 140 mg
    Bauhinia Purpurea L.(Leaf and Pod) Extract, Aegeline, Norcoclaurine HCl,
    Hemerocallis Fulva (Flower) Heat Concentrated Extract, Yohimbe (Pausinystalia Johimbe)
    (Bark) Extract (AlphaShred™)
  Caffeine 135 mg
OxyELITE Pro™ – Super Thermo Powder*
Serving Size 1–2 Scoops Amount per scoop
  OEP Thermo-Powder Blend 1058.5 mg
    ExerciseStim Matrix
      Choline Bitartrate, Caffeine Anhydrous (125 mg), Aegeline,
      Norcoclaurine HCl, Yohimbe (Pausinystalia Johimbe)(Bark) Extract (AlphaShred™)
  OTCN2 Carnitine Transport System
      L-Carnitine-Tartrate,(Z)-N-(2-hydroxyethyl)octadec-9-enamide,
      Eriobotrya Japonica (Leaf) Extract (Standardized for Ursane-Type Triterpenoids)
*Ingredient lists obtained from product labels.
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Table 2
Demographics of cases meeting investigation criteria for dietary supplement associated hepatotoxicity, Hawaii, 
2013 (N=44)
n %
Female gender 25 57




  Normal (<25) 11 25
  Overweight (25–29.9) 17 39
  Moderately Obese (30–34.9) 6 14
  Severely Obese (>35) 2 4
  Unknown/Refused 8 18
Comorbidities (as listed in the medical chart)a
  No comorbidities 22 50
  1–2 comorbidities 18 41
  3–5 comorbidities 4 9
Race
  White 1 2
  Asian 10 23
  Pacific Islander 1 2
  Black/African American 0
  American Indian/Alaska Native 0
  Two or more racesb 25 57
  Unknown 7 16
Duration of residence in Hawaii (years) Median 30.5,
Range 2–60
Case Status
  Probable 41 93
  Suspect 3 7
aComorbidities seen in ≥2 cases: obesity, hypertension, chronic headache/migraine, asthma, obstructive sleep apnea, hyperlipidemia, hypothyroid.
bComprising typically Asian, Pacific Islander, and/or Caucasian, as commonly observed among Hawaii’s population. Note that in 2012, of the 
18,986 births to 2 parents, 65% were reported to claim 2 races (unpublished data per HDOH Office of Health Status Monitoring).
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Table 3
Exposures of cases investigated for dietary supplement associated hepatotoxicity, Hawaii, 2013
n %
All Cases (N=44):
Dietary supplement exposure in the two months before illness
Any OxyELITE Pro™ 36 82
  OxyELITE Pro™ only 14 32
  OxyELITE Pro™ and another dietary supplement 22 50
Other supplements onlya 7 16
Unknown supplement 1 2
Other exposures
Tylenol® (general use) 13 30
NSAIDs (per medical chart or reported in the 3 weeks prior to onset) 18 41
Alcohol use (in the two months before onset) 22 50
  More than 4 beverages in a sitting 7 16
Cigarette/cigar smoking (ever) 12 27
Current smoker 5 11
Cases with any OxyELITE Pro™ use (N=36)
CIOMS scores (median score 5)
  0 (excluded) 0 0
  1–2(unlikely) 2 6
  3–5 (possible) 24 66
  6–8 (probable) 10 28
>8 (highly probable) 0 0
OxyELITE Pro™ formulation exposure in the two months before illness
  DMAA-free formulationsb only 27 75
  DMAA formulationc AND DMAA-free formulations 3 8
  DMAA formulation only 1 3
  Unknown formulation 5 14
Latency (Days from initial exposured to onset)
  Using estimated dates (n=31) Median 62, Range 7–732
  Using precise dates (n=9) Median 89, Range 12–422
a‘Other supplements’ include: multivitamins, protein shakes/powders, ‘Neem’, calcium carbonate, ‘Deca’, ‘Versa-1’, and ‘True-Slim’, as reported 
by cases.
bOxyELITE Pro NF, OxyELITE Pro Purple Top, OxyELITE Pro Powder, or OxyELITE Pro Advanced Formula.
cOxyELITE Pro Original Formula.
dInitial exposure could be earlier than 60 days before illness onset; the last exposure had to have been within 60 days of illness onset to meet case 
definition.
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